Comments
Granules India today said that the US health regulator has issued the Establishment Inspection Report (EIR) after completing the audit of its Telangana facility.
“The United States Food and Drug Administration (USFDA) has issued the Establishment Inspection Report (EIR) for the company’s Jeedimetla facility located at Hyderabad, Telangana, India,” Granules said in a BSE filing today.
The company said this facility was inspected by the USFDA in March 2018 and there was one observation during the inspection. Granules said it has responded to the observation within the stipulated timeframe.
Jeedimetla facility manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFIs), the company added.
The USFDA issues an EIR to the establishment that is subject to an FDA or FDA-contracted inspection when the agency decides to close the inspection. The company shares were trading up 2.48 per cent at Rs 97 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.